» Articles » PMID: 24293367

The Two Na+ Sites in the Human Serotonin Transporter Play Distinct Roles in the Ion Coupling and Electrogenicity of Transport

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2013 Dec 3
PMID 24293367
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Neurotransmitter transporters of the SLC6 family of proteins, including the human serotonin transporter (hSERT), utilize Na(+), Cl(-), and K(+) gradients to induce conformational changes necessary for substrate translocation. Dysregulation of ion movement through monoamine transporters has been shown to impact neuronal firing potentials and could play a role in pathophysiologies, such as depression and anxiety. Despite multiple crystal structures of prokaryotic and eukaryotic SLC transporters indicating the location of both (or one) conserved Na(+)-binding sites (termed Na1 and Na2), much remains uncertain in regard to the movements and contributions of these cation-binding sites in the transport process. In this study, we utilize the unique properties of a mutation of hSERT at a single, highly conserved asparagine on TM1 (Asn-101) to provide several lines of evidence demonstrating mechanistically distinct roles for Na1 and Na2. Mutations at Asn-101 alter the cation dependence of the transporter, allowing Ca(2+) (but not other cations) to functionally replace Na(+) for driving transport and promoting 5-hydroxytryptamine (5-HT)-dependent conformational changes. Furthermore, in two-electrode voltage clamp studies in Xenopus oocytes, both Ca(2+) and Na(+) illicit 5-HT-induced currents in the Asn-101 mutants and reveal that, although Ca(2+) promotes substrate-induced current, it does not appear to be the charge carrier during 5-HT transport. These findings, in addition to functional evaluation of Na1 and Na2 site mutants, reveal separate roles for Na1 and Na2 and provide insight into initiation of the translocation process as well as a mechanism whereby the reported SERT stoichiometry can be obtained despite the presence of two putative Na(+)-binding sites.

Citing Articles

Structural basis of vilazodone dual binding mode to the serotonin transporter.

Kalenderoglou I, Loland C, Nygaard A, Kalenderoglou I, Vogt C, Vogt C Res Sq. 2025; .

PMID: 39975905 PMC: 11838746. DOI: 10.21203/rs.3.rs-5671197/v1.


Fluorescent non-canonical amino acid provides insight into the human serotonin transporter.

Nygaard A, Zachariassen L, Larsen K, Kristensen A, Loland C Nat Commun. 2024; 15(1):9267.

PMID: 39463388 PMC: 11514162. DOI: 10.1038/s41467-024-53584-9.


Transport and inhibition mechanisms of the human noradrenaline transporter.

Hu T, Yu Z, Zhao J, Meng Y, Salomon K, Bai Q Nature. 2024; 632(8026):930-937.

PMID: 39085602 DOI: 10.1038/s41586-024-07638-z.


The substrate import mechanism of the human serotonin transporter.

Chan M, Selvam B, Young H, Procko E, Shukla D Biophys J. 2022; 121(5):715-730.

PMID: 35114149 PMC: 8943754. DOI: 10.1016/j.bpj.2022.01.024.


Effects of the N-terminal dynamics on the conformational states of human dopamine transporter.

Xu L, Chen L Biophys Chem. 2022; 283:106765.

PMID: 35101818 PMC: 8898274. DOI: 10.1016/j.bpc.2022.106765.


References
1.
Chen J, Rudnick G . External cysteine residues in the serotonin transporter. Biochemistry. 1997; 36(6):1479-86. DOI: 10.1021/bi962256g. View

2.
Hess B, Kutzner C, van der Spoel D, Lindahl E . GROMACS 4:  Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. J Chem Theory Comput. 2015; 4(3):435-47. DOI: 10.1021/ct700301q. View

3.
Tavoulari S, Rizwan A, Forrest L, Rudnick G . Reconstructing a chloride-binding site in a bacterial neurotransmitter transporter homologue. J Biol Chem. 2010; 286(4):2834-42. PMC: 3024779. DOI: 10.1074/jbc.M110.186064. View

4.
Tatsumi M, Groshan K, Blakely R, Richelson E . Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1998; 340(2-3):249-58. DOI: 10.1016/s0014-2999(97)01393-9. View

5.
Sneddon J . Sodium-dependent accumulation of 5-hydroxytryptamine by rat blood platelets. Br J Pharmacol. 1969; 37(3):680-8. PMC: 1703717. DOI: 10.1111/j.1476-5381.1969.tb08506.x. View